Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis

Circulation

Volumn 107, Issue 20, 2003, Pages 2601-2606

  Day, Sharlene M ^a,c   Duquaine, Damon ^a   Mundada, Lakshmi V ^a   Menon, Rekha G ^b   Khan, Bobby V ^b   Rajagopalan, Sanjay ^a   Fay, William P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Arteries; Free radicals; Thrombosis

Indexed keywords

11 OXOTHROMBOXANE B2; 6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; ALBUMIN; CHOLESTEROL; CYSTEINE; FREE RADICAL; IRON; IRON DEXTRAN; NITRIC OXIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOPLASTIN; THROMBOXANE A2;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; COLORIMETRY; CONTROLLED STUDY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; IRON OVERLOAD; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASODILATATION;

EID: 0038350932     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000066910.02844.d0     Document Type: Article

References (36)

1. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med. 1999;4:93-99.
2. Fairbanks VF. Hemochromatosis. population genetics. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge, England: Cambridge University Press; 2000:42-50.
3. Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799-1805.
4. de Valk B, Addicks MA, Gosriwatana I, et al. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest. 2000;30:248-251.
5. Edwards CQ. Hemochromatosis and other iron storage disorders. In: Lee GR, Blache D, Foerster J, et al, eds. Wintrobe's Clinical Hematology. Philadelphia, Pa: Lea & Febiger; 1993:872-884.
6. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation. 1992;86:803-811.
7. Tuomainen T-P, Kontula K, Nyyssonen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in Eastern Finland. Circulation. 1999;100:1274-1279.
8. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268-1273.
9. Smith C, Mitchinson MJ, Aruoma OI, et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
10. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984;74:1890-1894.
11. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest, 2001;107:1545-1553.
12. Lee T-S, Shiao M-S, Pan C-C, et al. Iron-deficient diet reduces atherosclerotic lesions in apoE-eficient mice. Circulation. 1999;99:1222-1229.
13. Araujo JA, Romano EL, Brito BE, et al. Iron overload augments the development of atherosclerotic lesions in rabbits. Art Thromb Vasc Biol. 1995;15:1172-1180.
14. Dabbagh AJ, Shwaery GT, Keaney JF Jr, et al. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol. 1997;17:2638-2645.
15. Danesh J, Appleby P. Coronary heart disease and iron status. Circulation. 1999;99:852-854.
16. Sullivan JL. Iron and the genetics of cardiovascular disease. Circulation. 1999;100:1260-1263.
17. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol. 2001;37:485-491.
18. Ambrosio G, Tritto I, Golino P. Reactive oxygen metabolites and arterial thrombosis. Cardiovasc Res. 1997;34:445-452.
19. Praticò D, Pasin M, Barry OP, et al. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation. 1999;99:3118-3124.
20. Penn MS, Cui M-Z, Winokur AL, et al. Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood. 2000;96:3056-3063.
21. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vasc Pharmacol. 2002;38:259-269.
22. Eitzman DT, Westrick RJ, Xu Z, et al, Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:1831-1834.
23. Singh R, Pan S, Mueske CS, et al. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 2001;89:71-76.
24. Kojda G, Laursen JB, Ramasamy S, et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res. 1999;42:206-213.
25. Ohba M, Shibanuma M, Kuroki T, et al. Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J Cell Biol. 1994;126:1079-1088.
26. Torrance JD, Bothwell TH. Tissue iron stores. In: Cook JD, ed. Methods in Hematology: Iron. New York, NY: Churchill Livingstone; 1980:90-113.
27. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002;22:662-666.
28. Morrow JD, Roberts LJ. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 1994;233:163-174.
29. Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996;2:35-40.
30. Saniabadi AR, Umemura K, Matsumoto N, et al. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost. 1995;73:868-872.
31. Polette A, Blache D. Effect of vitamin E on acute iron load-potentiated aggregation, secretion, calcium uptake and thromboxane biosynthesis in rat platelets. Atherosclerosis. 1992;96:171-179.
32. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804.
33. Rooyakkers TM, Stroes ESG, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002;32(suppl 1):9-16.
34. Gaenzer H, Marschang P, Sturm W, et al, Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002;40:2189-2194.
35. Yang EY, Campbell A, Bondy SC. Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Redox Report. 2000;5:371-375.
36. Anderson ME, Meister A. Intracellular delivery of cysteine. Methods Enzymol. 1987;143:313-325.